Holen Sie sich die Stockscreener-App
8.38
0.60%
0.05
Ocular Therapeutix Inc Aktie (OCUL) Neueste Nachrichten
Ameriprise Financial Inc. Purchases 40,700 Shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL) - Defense World
Two Sigma Investments LP Buys 45,518 Shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL) - Defense World
Nuveen Asset Management LLC Has $3.54 Million Stake in Ocular Therapeutix, Inc. (NASDAQ:OCUL) - Defense World
What is HC Wainwright’s Forecast for OCUL Q1 Earnings? - Defense World
Ocular gains as Wet AMD trial for lead asset reaches enrollment target - MSN
Ocular Therapeutix (NASDAQ:OCUL) Given Buy Rating at HC Wainwright - Defense World
Ocular Therapeutix (OCUL) Maintains "Buy" Rating with $15 Price Target | OCUL Stock News - GuruFocus
Millennium Management LLC Takes $3.82 Million Position in Ocular Therapeutix, Inc. (NASDAQ:OCUL) - Defense World
Ocular Therapeutix, Inc. (NASDAQ:OCUL) Stock Holdings Lessened by Bank of America Corp DE - Defense World
Demystifying Ocular Therapeutix: Insights From 7 Analyst Reviews - Benzinga
Ocular Therapeutix (OCUL) Advances with Axpaxli Trial Completion - GuruFocus
Ocular Therapeutix (NASDAQ:OCUL) Has Debt But No Earnings; Should You Worry? - simplywall.st
Sector Update: Health Care - marketscreener.com
Ocular Shares Rise After Eye Disease Trial Nears Enrollment Completion - marketscreener.com
Ocular stock gains after wet AMD trial update (OCUL:NASDAQ) - Seeking Alpha
Ocular Therapeutix chief scientific officer sells $21,712 in stock - Investing.com Australia
Ocular Therapeutix (OCUL) Concludes Enrollment for Key Retinal Trial | OCUL Stock News - GuruFocus
Ocular Therapeutix™ To Close Enrollment This Week for SOL-R, its - GuruFocus
Ocular Therapeutix™ To Close Enrollment This Week for - GlobeNewswire
Ocular Therapeutix™ To Close Enrollment This Week for SOL-R, its Second Registrational Trial Evaluating AXPAXLI™ in Wet Age-Related Macular Degeneration | OCUL Stock News - GuruFocus
Ocular Therapeutix™ To Close Enrollment This Week for SOL-R, its Second Registrational Trial Evaluating AXPAXLI™ in Wet Age-Related Macular Degeneration - Yahoo Finance
Ocular Therapeutix chief scientific officer sells $21,712 in stock By Investing.com - Investing.com Canada
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Has $755,000 Stock Position in Ocular Therapeutix, Inc. (NASDAQ:OCUL) - Defense World
D. E. Shaw & Co. Inc. Takes $268,000 Position in Ocular Therapeutix, Inc. (NASDAQ:OCUL) - Defense World
Ocular Therapeutix Executives Sell Shares to Cover Tax Obligations - TradingView
Ocular Therapeutix at Stifel 2025 Forum: Eyeing a Disruptive Future By Investing.com - Investing.com Canada
(OCUL) Trading Report - news.stocktradersdaily.com
BNP Paribas Financial Markets Acquires 39,599 Shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL) - Defense World
Ocular Therapeutix, Inc. (NASDAQ:OCUL) Receives Average Recommendation of “Moderate Buy” from Brokerages - Defense World
Ocular Therapeutix at BioConnect: Strategic Advances in Wet AMD Treatment By Investing.com - Investing.com Canada
Ocular Therapeutix, Inc. (NASDAQ:OCUL) Holdings Boosted by Northern Trust Corp - Defense World
Ocular Therapeutix™ to Participate in Upcoming Investor Conferences - GlobeNewswire
Ocular Therapeutix CEO to Present at RBC, Mizuho, and Top Healthcare Conferences: Key Dates for Investors - Stock Titan
The Manufacturers Life Insurance Company Sells 2,399 Shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL) - Defense World
Transcript : Ocular Therapeutix, Inc. Presents at BofA Securities 2025 Healthcare Conference, May-13-2025 09 - marketscreener.com
Hsbc Holdings PLC Buys 5,853 Shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL) - Defense World
Tower Research Capital LLC TRC Has $76,000 Stock Position in Ocular Therapeutix, Inc. (NASDAQ:OCUL) - Defense World
HC Wainwright Analysts Reduce Earnings Estimates for OCUL - Defense World
William Blair Brokers Decrease Earnings Estimates for OCUL - Defense World
Analysts Offer Predictions for OCUL FY2026 Earnings - Defense World
Ocular Therapeutix at The Citizens JMP Life Sciences Conference: Strategic Insights - Investing.com India
Bearish: Analysts Just Cut Their Ocular Therapeutix, Inc. (NASDAQ:OCUL) Revenue and EPS estimates - simplywall.st
Analysts Just Slashed Their Ocular Therapeutix, Inc. (NASDAQ:OCUL) EPS Numbers - Yahoo Finance
Ocular Therapeutix (NASDAQ:OCUL) Trading Down 6.5% on Analyst Downgrade - Defense World
Analyst Expectations For Ocular Therapeutix's Future - Benzinga
Ocular Therapeutix (OCUL) Maintained as Buy by Needham, Price Ta - GuruFocus
Ocular Therapeutix First Quarter 2025 Earnings: Misses Expectations - Yahoo
Ocular Therapeutix Advances in Retinal Treatment Trials - TipRanks
Decoding Ocular Therapeutix Inc (OCUL): A Strategic SWOT Insight - GuruFocus
Ocular Therapeutix: Q1 Earnings Snapshot - MySA
Ocular Therapeutix sees cash runway into 2028 - TipRanks
Ocular Therapeutix (OCUL) Stock Drops 13% After Q1 Earnings - Benzinga
Ocular Therapeutix reports Q1 EPS (38c), consensus (28c) - TipRanks
0.00%
0.54%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):